04/23/2025 11:56
QPS Expands Offerings With Robust Pharmacology Disease Models, Including MASH, Ulcerative Colitis, Wound Healing, and Psoriasis

QPS, a leading global contract research organization (CRO) specializing in preclinical and clinical drug development services, is pleased to announce the expansion of its pharmacology disease models portfolio to include highly relevant and sophisticated models for metabolic dysfunction-associated steatohepatitis (MASH), ulcerative colitis (UC), wound healing, and psoriasis. These new disease models provide the biomedical community with advanced tools for evaluating potential therapeutic candida...

04/23/2025 11:55
Imricor Commences VISABL-VT Trial

Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce that it has commenced the VISABL-VT clinical trial by completing the first-in-human ventricular ablation guided by real-time MRI with the Company’s NorthStar Mapping System. The procedure was performed by the team at the Amsterdam University Medical Centre (AUMC), ranked in 2025 by Newsweek as the best hospital in The Netherlands, and in the top 35 worldwide. This press release features multimedia. View the ful...

05/01/2025 15:16
Giovanni Brienza Appointed President of Frontline International

Frontline International, celebrating 25 years of innovation in commercial kitchen solutions, has appointed Giovanni Brienza as its new president. Founder John Palazzo will continue as CEO, focusing on strategic direction and long-term growth initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501026483/en/Giovanni Brienza, Frontline International President Frontline is a USA-based manufacturer of systems used globally by f...

AFP and Italy’s Fort Bard renew their partnership with the launch of a second exhibition

Following the success of their first collaboration, AFP and Fort Bard have unveiled their latest exhibition, "Contrasts. Stories from a World on Edge," which will be on display until 20 July, 2025.

Following the success of their first collaboration, AFP and Fort Bard have unveiled their latest exhibition, "Contrasts. Stories from a World on Edge," which will be on display until 20 July, 2025.
05/01/2025 15:31
Textron Aviation Calls on Cessna, Beechcraft and Hawker Owners to Transport Athletes to the 2026 Special Olympics USA Games

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the coordination of the ninth Special Olympics Airlift, a monumental event aimed at transporting hundreds of athletes and coaches across country to the 2026 Special Olympics USA Games in Minnesota’s Twin Cities. The company is calling on Cessna, Beechcraft and Hawker aircraft owners and operators to come together on Friday, June 19, 2026, and Saturday, June 27, 2026, to enable champions from all corners of the nation to t...

03/11/2025 12:30
Telness Tech Brings European Technology to U.S. MVNOs on the T-Mobile Network

Telness Tech is excited to announce the availability of their services to Mobile Virtual Network Operators (MVNOs) on the T-Mobile network, one of the world’s most advanced mobile networks with nationwide 5G Standalone. This opportunity allows for the integration of Telness Tech’s BSS/OSS platform with T-Mobile’s 5G network, helping MVNOs in the U.S. to launch and grow their services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2025...

AFP’s 2022 results: 5% growth in commercial revenues, new tensions on costs

At its meeting on 20 April 2023, AFP's Board of Directors approved the accounts for the 2022 financial year, which confirm the Agency's continued financial recovery.

At its meeting on 20 April 2023, AFP's Board of Directors approved the accounts for the 2022 financial year, which confirm the Agency's continued financial recovery.
Anglais
03/18/2025 08:00
Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova’s biotech acceleration strategy, extending beyond Italy to inclu...